Home - Products - Others - Other Targets - (6,7-dimethoxyisoquinolin-1-yl)(4-methoxyphenyl)methanone

(6,7-dimethoxyisoquinolin-1-yl)(4-methoxyphenyl)methanone

CAS No. 20359-10-8

(6,7-dimethoxyisoquinolin-1-yl)(4-methoxyphenyl)methanone( ——— )

Catalog No. M39366 CAS No. 20359-10-8

(6,7-dimethoxyisoquinolin-1-yl)(4-methoxyphenyl)methanone

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    (6,7-dimethoxyisoquinolin-1-yl)(4-methoxyphenyl)methanone
  • Note
    Research use only, not for human use.
  • Brief Description
    (6,7-dimethoxyisoquinolin-1-yl)(4-methoxyphenyl)methanone
  • Description
    (6,7-dimethoxyisoquinolin-1-yl)(4-methoxyphenyl)methanone
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    20359-10-8
  • Formula Weight
    ———
  • Molecular Formula
    ———
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Cefmetazole sodium

    Cefmetazole sodium is a semisynthetic cephamycin antibiotic.

  • LY-294002 hydrochlor...

    LY294002 is a synthetic molecule inhibitor of PI3Kα/δ/β (IC50: 0.5/0.57/0.97 μM, in cell-free assays); more stable than Wortmannin in solution, and also is a blocker of autophagosome formation.

  • ZINC77292789

    Fmoc-Thr[GalNAc(Ac)3-α-D]-OH is a reagent for the preparation of a synthetic MUC1 Glycopeptide Bearing βGalNAc-?Thr as a Tn antigen isomer which induces the antibody production against tumor cells. Fmoc-Thr[GalNAc(Ac)3-α-D]-OH is a starting material to make trimeric MUC1 immunodominant motif antigen-?based anti-?cancer vaccine candidates.